SSH.COM
SSH.COM today announced that their access management gateway solution, PrivX , is now available for free in limited host environments to give IT and software teams all over the world the opportunity to enjoy the benefits of lean, scalable and automated access management to hybrid and multi-cloud (AWS, GCP, Azure, OpenStack) servers and applications.
Cloudification has changed the face of software development and deployment and IT management; modern techniques in software delivery require that trusted access management is in lockstep with development cycles, such as those used in the Continuous Integration/Continuous Delivery (CI/CD) models, while servers are located across on-prem, virtual private cloud (VPC) and multi-cloud environments. Extra steps, bottlenecks and manual processes simply don’t fit into that equation; it’s all about elasticity and automation.
SSH.COM’s Chief Customer Officer, Sami Ahvenniemi: “Spurred on by the shift to the cloud, we have identified that many our customers are looking for the following types of solutions:
- Modern and lean administrative access management tools
- Zero Trust solutions that manage access to critical assets, inside the perimeter
- Automated, scalable alternatives to in-house jump hosts and VPNs
- Centralized 3rd party access controls with monitoring and session recording
The focus is now on the entire access lifecycle of employees, including new hires, people moving around the organization, and people leaving the company. For example, developers, admins and external contractors are all needed - often temporarily - for various tasks with different levels of privilege, all within the critical IT infrastructure. Further, companies and teams often want to start small and scale IT management tools as needed, without taking on the burden of massive IT projects or turning their infrastructure into a hard-to-maintain and complex system. With PrivX, they get an access management solution that deploys in a matter of days, practically updates itself, provides monitoring of access traffic and delivers a simple user experience.”
SSH.COM’s PrivX offers just-in-time role-based access controls to multi-cloud and on-premises resources in development and production environments. Access authorization is never permanent but is based on short-lived certificates that expire within a few minutes of establishing the RDP/SSH connection. PrviX is an agentless and credentialess solution that integrates with existing identity access management (IAM) and directory service (AD/LDAP) tools as well as cloud-hosted servers and applications, including auto-discovery of cloud hosts.
SSH.COM is now making PrivX available free of charge online . Companies can start small and scale with PrivX as their business needs grow.
Mr. Ahvenniemi continued, “Cloud and hybrid environments require technological solutions that emphasize speed and agility over legacy products that are patched up to fit the needs of the cloud. That is why we built PrivX.”
Learn more about PrivX:
- Visit our PrivX product page .
- Download the PrivX datasheet .
- PrivX is reviewed in Kuppinger Cole’s Executive View Report .
- Read about PrivX and its ephemeral certificate-based authentication in our white paper .
About SSH.COM
SSH.COM helps organizations access, secure and control their digital core – their critical data, applications and services. We have over 3,000 customers around the world, including 40 percent of Fortune 500 companies, many of the world’s largest financial institutions, and major organizations in all verticals. We are committed to helping our customers thrive in the cloud era with solutions that offer secure access with zero inertia, zero friction and zero credentials risk. SSH.COM sells online; through offices in North America, Europe and Asia; and through a global network of certified partners. The company’s shares (SSH1V) are quoted on the NASDAQ Helsinki. For more information, visit www.ssh.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190607005053/en/
Contact:
SSH.COM Contact : Simo Karkkulainen SSH.COM +358 40 738 9406 simo.karkkulainen@ssh.com SSH.COM Agency Contact : Hanah Johnson March Communications +1 617-960-8892 ssh@marchcomms.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom